Amin Khalifa - Avivagen Insider

VIV -- Canada Stock  

CAD 0.63  0.07  10.00%

Independent Director
Mr. Amin I. Khalifa is Independent Director of Avivagen Inc. He was Oct 2010 to present CFO Corporationrationrate Vice President, Iris International Inc., January 2008 to September 2010 Principal Khalifa Management Consulting, August 2006 to September 2007 Executive Vice President CFO Leap Wireless, August 2003 to August 2006 Executive Vice President CFO Apria Healthcare.
  Director Since 2011      
613-949-8164  http://www.avivagen.com

Management Efficiency

The company has return on total asset (ROA) of (57.97) % which means that it has lost $57.97 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE) of (312.77) % meaning that it generated substantial loss on money invested by shareholders.
The company has accumulated 1.22 M in total debt with debt to equity ratio (D/E) of 45.8 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Avivagen has Current Ratio of 5.93 suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due.

Similar Executives

Showing few of many executives

DIRECTOR Since

Heather MunroeBlumRoyal Bank of Canada
2011
V YoungRoyal Bank of Canada
1991
Claude MongeauThe Toronto Dominion Bank
2015
Timothy HearnRoyal Bank of Canada
2006
Maureen McCawSuncor Energy
2004
Ashleigh EverettThe Bank of Nova Scotia
1997
JeanRene HaldeThe Toronto Dominion Bank
2015
Sung ChiuCNOOC Limited
1999
Michael CreelSuncor Energy
2016
Andrew ChisholmRoyal Bank of Canada
2016
Wilbur PrezzanoThe Toronto Dominion Bank
2003
Helen SinclairThe Toronto Dominion Bank
1996
Irene MillerThe Toronto Dominion Bank
2006
Jacynthe CoteRoyal Bank of Canada
2014
John GassSuncor Energy
2014
Eira ThomasSuncor Energy
2006
Thomas RenyiRoyal Bank of Canada
2013
William BeattieRoyal Bank of Canada
2001
William FattThe Bank of Nova Scotia
2015
Amy BrinkleyThe Toronto Dominion Bank
2010
Una PowerThe Bank of Nova Scotia
2016

Entity Summary

Avivagen, Inc. develops and commercializes various products to replace antibiotics in livestock feeds to optimize the health and growth of the animals by supporting the animals own health defenses. The company was formerly known as Chemaphor, Inc. and changed its name to Avivagen, Inc. in May 2012. Avivagen is traded on TSX Venture Exchange in Canada.Avivagen (VIV) is traded on TSX Venture Exchange in Canada. It is located in 100 Sussex Drive and employs 19 people.

Avivagen Leadership Team

David Hankinson, Director
Louis Hui, Director
Chris Boland, CFO
David Allan, Director
Amin Khalifa, Director
Aubrey Dan, Director
Cameron Groome, CEO
Vanessa Grant, Director
Andrew Basek, Director, MBA
Drew Basek, Director, MBA
Paul Mesburis, Director
Graham Burton, Director, Ph.D
G Anthony, Director

Stock Performance Indicators

Current Sentiment - VIV

Avivagen Investor Sentiment
Most of Macroaxis users are at this time bullish on Avivagen. What is your sentiment towards investing in Avivagen? Are you bullish or bearish?
Bullish
Bearish
98% Bullish
2% Bearish
Skip

Also Currentnly Active

Purchased over 40 shares of
few days ago
Traded for 62.4
Purchased over 30 shares of
few days ago
Traded for 83.93
Purchased over 20 shares of
few days ago
Traded for 101.16
Also please take a look at World Market Map. Please also try Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.